A Boxed Warning was included in the prescribing information highlighting the risk of serious liver injury and acute liver failure. The Food and Drug Administration (FDA) has approved new safety ...
DYNE-251 received FDA breakthrough therapy designation for DMD, showing promising clinical evidence of improvement over existing therapies. The DELIVER trial demonstrated sustained functional ...
– Fast Track designation aims to facilitate development and expedite review of drugs, such as PBGENE-DMD to treat serious conditions like Duchenne muscular dystrophy – – March 17, 2026 virtual webinar ...
The guidance explains how treatment planning, diagnostics, and insurance factors influence full-mouth dental implant ...
- New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history - - Data expand on previously reported results demonstrating that ...
Duchenne muscular dystrophy (DMD) occurs as a result of genetic changes on the X chromosome. If someone has a gene change that can cause DMD, their children may inherit that change. DMD is a ...
Duchenne muscular dystrophy (DMD) causes muscle weakness that becomes more severe over time. While there is no cure, treatments can help slow the progression and manage symptoms and complications.
Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy – U.S. FDA Study May Proceed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results